Healthcare News Roundup: FDA, NHS and EMA Decisions July 2026

• A recent AJMC podcast highlighted the critical underutilization of the FIB4 liver screening tool, which Dr. Chika Anekwe describes as a noninvasive, guideline-supported method for detection. • Dr. Naim Alkhouri noted that FDA approvals for resmetirom and semaglutide to treat aggressive metabolic dysfunction-associated steatohepatitis (MASH) have increased the urgency for early screening.

• A comprehensive review published in The Lancet reaffirms that approved mRNA vaccines are safe and highly effective across diverse populations, including children and immunocompromised patients. • Led by researchers from the University of British Columbia and Imperial College London, the study analyzed data from billions of doses, combining clinical trials with real-world surveillance.

• The U.S. Food and Drug Administration (FDA) is investigating reports of neurological complications in patients of Venezuelan ancestry following the administration of anesthesia. • The probe focuses on identifying a potential link between specific anesthetic agents and adverse neurological reactions unique to this demographic.

• The World Health Organization (WHO) has launched the "Partners" clinical trial in the Democratic Republic of Congo to test treatments for the Bundibugyo Ebola virus. • The study will evaluate the efficacy of MBP-134 and remdesivir in up to 1,200 patients currently affected by the outbreak.

• Genmab's epcoritamab showed successful results in treating diffuse large B-cell lymphoma (DLBCL), while BRUKINSA achieved a win in treating mantle cell lymphoma (MCL). • The FDA approved Tregzi for the treatment of graft-versus-host disease (GVHD), providing a critical new tool for patients undergoing allogeneic stem cell transplantation.

• A randomized platform trial has launched in the Democratic Republic of Congo to evaluate therapies for the Bundibugyo virus, a strain of Ebola with no existing licensed vaccines or treatments. • The study tests whether the monoclonal antibody MBP134, the antiviral drug remdesivir, or a combination of both can improve survival rates across patients of all ages.

• A study published in Nature Health on June 15, 2026, reveals that new antidepressant prescriptions in England have fallen below pre-pandemic levels. • The research analyzed primary care dispensing data spanning from 2019 to 2024 to track prescribing trends across the country.

• Tuberculosis cases in the U.S. reached a 14-year high in 2024 and remain elevated in 2025, sparking alarm among public health experts. • The surge is attributed to critical gaps in screening and underfunded contact tracing, which leave vulnerable communities exposed to the disease.

• The World Health Organization (WHO) has launched a clinical trial for two Ebola therapeutics in the Democratic Republic of Congo, enrolling the first patient this Thursday. • The trial aims to reduce mortality rates during an outbreak that began in May and has already resulted in 1,406 confirmed cases and 438 deaths.

• The U.S. healthcare system is facing a potential crisis as a Supreme Court ruling could pave the way for mass deportations. • Experts warn that these deportations would exacerbate existing staffing shortfalls in hospitals and emergency rooms, with the long-term healthcare sector expected to suffer the most significant disruptions.

• The FDA updated a Salmonella outbreak warning on June 30, 2026, reporting 119 illnesses across 36 states, including 32 hospitalizations. • The expanded recall now includes products from TNVitamins, Live it Up, Doctor's Pride, and Why Not Natural.